20 Myths About Personalized Depression Treatment: Busted > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many suffering from depression, traditional therapies and medication are ineffective. The individual approach to treatment could be the answer.

Cue is an intervention platform that converts sensor data collected from smartphones into personalised micro-interventions for improving mental health. We analyzed the best-fitting personalized ML models for each individual using Shapley values to determine their characteristic predictors. This revealed distinct features that deterministically changed mood over time.

Predictors of Mood

Depression is the leading cause of mental illness across the world.1 Yet, only half of those suffering from the condition receive treatment. In order to improve outcomes, healthcare professionals must be able to identify and treat patients who have the highest probability of responding to certain treatments.

A customized depression treatment is one method of doing this. Using mobile phone sensors and an artificial intelligence voice assistant and other digital tools researchers at the University of Illinois Chicago (UIC) are developing new methods to predict which patients will benefit from the treatments they receive. Two grants totaling more than $10 million will be used to identify biological and behavioral indicators of response.

To date, the majority of research into predictors of depression treatment effectiveness (humanlove.stream) has been focused on clinical and sociodemographic characteristics. These include factors that affect the demographics like age, sex and education, clinical characteristics such as symptoms severity and comorbidities and biological markers like neuroimaging and genetic variation.

Few studies have used longitudinal data to determine mood among individuals. They have not taken into account the fact that mood can vary significantly between individuals. Therefore, it is crucial to develop methods that allow for the identification of different mood predictors for each person and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team can then develop algorithms to identify patterns of behavior and emotions that are unique to each individual.

The team also developed an algorithm for machine learning to create dynamic predictors for each person's depression mood. The algorithm blends these individual variations into a distinct "digital phenotype" for each participant.

The digital phenotype was associated with CAT DI scores, a psychometrically validated symptom severity scale. The correlation was low, however (Pearson r = 0,08; BH adjusted P-value 3.55 x 10 03) and varied significantly between individuals.

Predictors of Symptoms

Depression is among the world's leading causes of disability1, but it is often not properly diagnosed and depression treatment effectiveness treated. In addition an absence of effective interventions and stigmatization associated with depressive disorders prevent many people from seeking help.

alternative ways to treat depression aid in the development of a personalized treatment, it is important to determine the predictors of symptoms. The current prediction methods rely heavily on clinical interviews, which are unreliable and only identify a handful of features associated with depression.

Machine learning can be used to integrate continuous digital behavioral phenotypes that are captured by sensors on smartphones and a validated online mental depression treatment health tracker (the Computerized Adaptive Testing Depression Inventory CAT-DI) along with other indicators of severity of symptoms can increase the accuracy of diagnostics and the effectiveness of treatment for depression. These digital phenotypes capture a large number of distinct actions and behaviors that are difficult to capture through interviews, and allow for high-resolution, continuous measurements.

The study involved University of California Los Angeles (UCLA) students experiencing moderate to severe depressive symptoms. enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29 that was created under the UCLA Depression Grand Challenge. Participants were directed to online support or in-person clinical care depending on their depression severity. Those with a score on the CAT-DI of 35 or 65 were assigned online support by a coach and those with a score 75 were sent to in-person clinical care for psychotherapy.

At baseline, participants provided a series of questions about their personal demographics and psychosocial features. The questions asked included education, age, sex and gender, marital status, financial status, whether they were divorced or not, current suicidal thoughts, intent or attempts, as well as the frequency with which they consumed alcohol. The CAT-DI was used to assess the severity of depression-related symptoms on a scale of zero to 100. CAT-DI assessments were conducted every other week for the participants that received online support, and weekly for those receiving in-person care.

Predictors of Treatment Reaction

A customized treatment for depression is currently a major research area, and many studies aim at identifying predictors that help clinicians determine the most effective medication for each person. Pharmacogenetics, for instance, identifies genetic variations that determine how the human body metabolizes drugs. This allows doctors to select medications that are likely to work best for each patient, while minimizing the time and effort required in trial-and-error procedures and avoiding side effects that might otherwise slow the progress of the patient.

Another approach that is promising is to build prediction models that combine the clinical data with neural imaging data. These models can be used to determine the best combination of variables predictive of a particular outcome, like whether or not a particular medication will improve the mood and symptoms. These models can also be used to predict the patient's response to an existing treatment, allowing doctors to maximize the effectiveness of treatment currently being administered.

A new generation employs machine learning techniques such as algorithms for classification and supervised learning, regularized logistic regression and tree-based methods to combine the effects from multiple variables to improve the accuracy of predictive. These models have been proven to be useful in predicting treatment outcomes such as the response to antidepressants. These techniques are becoming increasingly popular in psychiatry and could be the norm in future treatment.

Research into depression's underlying mechanisms continues, as well as ML-based predictive models. Recent research suggests that depression is linked to dysfunctions in specific neural networks. This suggests that an individualized treatment for depression will depend on targeted therapies that restore normal function to these circuits.

Internet-delivered interventions can be an option to achieve this. They can offer an individualized and tailored experience for patients. For example, one study found that a program on the internet was more effective than standard treatment in alleviating symptoms and ensuring an improved quality of life for people suffering from MDD. A controlled, randomized study of a customized treatment for depression showed that a significant number of patients saw improvement over time and had fewer adverse consequences.

Predictors of side effects

In the treatment of depression the biggest challenge is predicting and identifying the antidepressant that will cause no or minimal adverse negative effects. Many patients are prescribed a variety of drugs before they find a drug that is effective and tolerated. Pharmacogenetics is an exciting new method for an efficient and specific method of selecting antidepressant therapies.

There are many predictors that can be used to determine which antidepressant should be prescribed, including gene variations, phenotypes of patients such as gender or ethnicity and co-morbidities. However, identifying the most reliable and reliable factors that can predict the effectiveness of a particular treatment will probably require controlled, randomized trials with much larger samples than those normally enrolled in clinical trials. This is because it may be more difficult to detect interactions or moderators in trials that only include one episode per participant rather than multiple episodes over time.

Furthermore, the prediction of a patient's reaction to a specific medication will also likely require information about the symptom profile and comorbidities, as well as the patient's previous experiences with the effectiveness and tolerability of the medication. Currently, only a few easily assessable sociodemographic variables and clinical variables seem to be reliably related to response to MDD. These include gender, age, race/ethnicity, BMI, SES and the presence of alexithymia.

There are many challenges to overcome in the application of pharmacogenetics in the treatment of depression. first line treatment for anxiety and depression it is necessary to have a clear understanding of the genetic mechanisms is essential, as is an understanding of what is a reliable indicator of treatment response. In addition, ethical issues like privacy and the ethical use of personal genetic information must be carefully considered. The use of pharmacogenetics may be able to, over the long term, reduce stigma surrounding treatments for mental illness and improve the outcomes of treatment. As with all psychiatric approaches, it is important to take your time and carefully implement the plan. For now, the best method is to provide patients with various effective medications for depression and encourage them to talk freely with their doctors about their experiences and concerns.